JPH2

Across TCGA pan-cancer cohorts, JPH2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated JPH2 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher JPH2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated JPH2 expression acts as an unfavorable survival marker.

LUAD, GBM, and LSCC are the cancer types where JPH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.866	0.992	.012	20	view →
GBM	DFS	Tertile	All	0.609	0.825	.006	14	view →
LSCC	DFS	Median	II,III,IV	0.565	0.814	.034	7	view →
PDAC	DFS	Quartile	All	0.739	0.922	.008	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

JPH2–LUAD (DFS)

Open the LUAD breakdown →